These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 9625329)

  • 1. A randomized controlled trial of interferon-alpha in patients with cirrhosis caused by 2a/2b genotype hepatitis C virus.
    Ikeda K; Kumada H; Saitoh S; Suzuki Y; Kobayashi M; Tsubota A; Koida I; Fukuda M; Arase Y; Chayama K; Murashima N; Tango T
    J Hepatol; 1998 May; 28(5):910-1. PubMed ID: 9625329
    [No Abstract]   [Full Text] [Related]  

  • 2. Interferon-alpha therapy for hepatitis C virus infection after liver transplantation.
    Wright TL; Combs C; Kim M; Ferrell L; Bacchetti P; Ascher N; Roberts J; Wilber J; Sheridan P; Urdea M
    Hepatology; 1994 Oct; 20(4 Pt 1):773-9. PubMed ID: 7927216
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical decisions. Management of incidental hepatitis C virus infection.
    Afdhal NH; Lok AS; Di Bisceglie AM
    N Engl J Med; 2009 Apr; 360(18):1902-6. PubMed ID: 19403909
    [No Abstract]   [Full Text] [Related]  

  • 4. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM.
    Douglas DD; Rakela J; Lin HJ; Hollinger FB; Taswell HF; Czaja AJ; Gross JB; Anderson ML; Parent K; Fleming CR
    Dig Dis Sci; 1993 Apr; 38(4):601-7. PubMed ID: 8384978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preferential virological response to interferon-alpha 2a in patients with chronic hepatitis C infected by virus genotype 3a and exhibiting a low gamma-GT/ALT ratio.
    Mihm S; Hartmann H; Fayyazi A; Ramadori G
    Dig Dis Sci; 1996 Jun; 41(6):1256-64. PubMed ID: 8654161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.
    De Rosa FG; Bargiacchi O; Audagnotto S; Garazzino S; Cariti G; Raiteri R; Di Perri G
    J Antimicrob Chemother; 2006 Feb; 57(2):360-3. PubMed ID: 16396921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to alpha 2B interferon (IFN) treatment in a haemodialysis patient with chronic hepatitis C.
    Barril G; Schez Tomero JA; Garcia Buey L; Motellon JL; Bernis C; Traver JA
    Nephrol Dial Transplant; 1994; 9(9):1354-5. PubMed ID: 7816309
    [No Abstract]   [Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled trial of recombinant human alpha-interferon therapy for chronic non-A, non-B (type C) hepatitis.
    Di Bisceglie AM; Martin P; Kassianides C; Lisker-Melman M; Goodman Z; Banks SM; Hoofnagle JH
    J Hepatol; 1990; 11 Suppl 1():S36-42. PubMed ID: 2127786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of chronic hepatitis C with recombinant interferon alpha 2b.
    Terranova R; Luca S
    J Chemother; 1992 Oct; 4(5):297-302. PubMed ID: 1479419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of alpha-glutathione S-transferase in the monitoring of hemodialysis patients with hepatitis C virus infection undergoing high-dose interferon-alpha-2b therapy.
    Boran M; Cetin S
    Nephron; 1999; 82(1):22-6. PubMed ID: 10224480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of acute non-A, non-B hepatitis with interferon alpha-2b.
    Tassopoulos NC; Koutelou M; Papatheodoridis G; Polychronaki H; Giannikakis T; Paraloglou-Ioannides M; Hatzakis A
    Infection; 1992; 20(4):242. PubMed ID: 1521895
    [No Abstract]   [Full Text] [Related]  

  • 13. Response related factors in recombinant interferon alfa-2b treatment of chronic hepatitis C.
    Pérez R; Pravia R; Linares A; Rodríguez M; Lombraña JL; Suárez A; Riestra S; Navascués CA; Rodrigo L
    Gut; 1993; 34(2 Suppl):S139-40. PubMed ID: 8314482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis.
    Bresci G; Del Corso L; Romanelli AM; Giuliano G; Pentimone F
    J Am Geriatr Soc; 1993 Aug; 41(8):857-62. PubMed ID: 7688007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged treatment (2 years) with different doses (3 versus 6 MU) of interferon alpha-2b for chronic hepatitis type C. Results of a multicenter randomized trial.
    Saracco G; Borghesio E; Mesina P; Solinas A; Spezia C; Macor F; Gallo V; Chiandussi L; Donada C; Donadon V; Spirito F; Mangia A; Andriulli A; Verme G; Rizzetto M
    J Hepatol; 1997 Jul; 27(1):56-62. PubMed ID: 9252074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic hepatitis C with high-dose interferon alpha-2b. A multicenter study.
    Iino S; Hino K; Kuroki T; Suzuki H; Yamamoto S
    Dig Dis Sci; 1993 Apr; 38(4):612-8. PubMed ID: 8384980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Autoimmune hepatitis type 1 revealed during treatment with interferon].
    Tran A; Beusnel C; Montoya ML; Lussiez V; Hébuterne X; Rampal P
    Gastroenterol Clin Biol; 1992; 16(8-9):722-3. PubMed ID: 1426834
    [No Abstract]   [Full Text] [Related]  

  • 18. Pegylated interferon alpha-2b in patients with acute hepatitis C.
    Mukhopadhyay A
    Natl Med J India; 2006; 19(4):201-2. PubMed ID: 17100108
    [No Abstract]   [Full Text] [Related]  

  • 19. A multicenter randomized controlled trial of recombinant interferon-alpha 2b in patients with acute transfusion-associated hepatitis C.
    Lampertico P; Rumi M; Romeo R; Craxì A; Soffredini R; Biassoni D; Colombo M
    Hepatology; 1994 Jan; 19(1):19-22. PubMed ID: 7506225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
    Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
    J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.